Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 18Other hematologic neoplasm 10Lymphoid 8Thoracic 1Sarcoma 1

Conditions

Sarcoma 523Glioblastoma 179Gliosarcoma 178Osteosarcoma 155Dendritic Cell Sarcoma, Interdigitating 114Brain Neoplasms 113Gastrointestinal Stromal Tumors 108Central Nervous System Neoplasms 102Rhabdomyosarcoma 81Lymphoma 79Glioma 79Burkitt Lymphoma 79Lymphoma, Non-Hodgkin 78Recurrence 76Leiomyosarcoma 75Precursor Cell Lymphoblastic Leukemia-Lymphoma 73Lymphoma, Large B-Cell, Diffuse 70Liposarcoma 69Astrocytoma 68Sarcoma, Ewing 67Lymphoma, Follicular 63Neuroblastoma 60Lymphoma, Mantle-Cell 58Leukemia, Lymphocytic, Chronic, B-Cell 57Lymphoma, B-Cell, Marginal Zone 56Lymphoma, Large-Cell, Immunoblastic 54Hodgkin Disease 54Leukemia, Myeloid, Acute 53Neuroectodermal Tumors, Primitive, Peripheral 52Neoplasm Metastasis 51

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Mastocytosis, Systemic × Sarcoma × Clear all
NCT00171912 2017-02-23

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Novartis

Phase 2 Completed
38 enrolled
MyeloidOther hematologic neoplasmSarcomaThoracic

Lung Neoplasms, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Dermatofibrosarcoma, Mastocytosis, Systemic, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡